JBIO Bull Call Spread Strategy
JBIO (Jade Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO (Jade Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $817.9M, a beta of 1.52 versus the broader market, a 52-week range of 6.565-28, average daily share volume of 548K, a public-listing history dating back to 2025, approximately 50 full-time employees. These structural characteristics shape how JBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.52 indicates JBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. JBIO pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a bull call spread on JBIO?
A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width.
Current JBIO snapshot
As of May 15, 2026, spot at $23.54, ATM IV 152.80%, IV rank 24.68%, expected move 43.81%. The bull call spread on JBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this bull call spread structure on JBIO specifically: JBIO IV at 152.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a JBIO bull call spread, with a market-implied 1-standard-deviation move of approximately 43.81% (roughly $10.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on JBIO should anchor to the underlying notional of $23.54 per share and to the trader's directional view on JBIO stock.
JBIO bull call spread setup
The JBIO bull call spread below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JBIO near $23.54, the first option leg uses a $23.54 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $23.54 | N/A |
| Sell 1 | Call | $24.72 | N/A |
JBIO bull call spread risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit.
JBIO bull call spread payoff curve
Modeled P&L at expiration across a range of underlying prices for the bull call spread on JBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use bull call spread on JBIO
Bull call spreads on JBIO reduce the cost of a bullish JBIO stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
JBIO thesis for this bull call spread
The market-implied 1-standard-deviation range for JBIO extends from approximately $13.23 on the downside to $33.85 on the upside. A JBIO bull call spread caps both the risk and the reward of a bullish position; relative to an outright long call on JBIO, the spread reduces the cost basis but limits the maximum profit to the strike width minus net debit. Current JBIO IV rank near 24.68% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JBIO at 152.80%. As a Healthcare name, JBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JBIO-specific events.
JBIO bull call spread positions are structurally moderately bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JBIO alongside the broader basket even when JBIO-specific fundamentals are unchanged. Long-premium structures like a bull call spread on JBIO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current JBIO chain quotes before placing a trade.
Frequently asked questions
- What is a bull call spread on JBIO?
- A bull call spread on JBIO is the bull call spread strategy applied to JBIO (stock). The strategy is structurally moderately bullish: A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width. With JBIO stock trading near $23.54, the strikes shown on this page are snapped to the nearest listed JBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JBIO bull call spread max profit and max loss calculated?
- Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit. For the JBIO bull call spread priced from the end-of-day chain at a 30-day expiry (ATM IV 152.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JBIO bull call spread?
- The breakeven for the JBIO bull call spread priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JBIO market-implied 1-standard-deviation expected move is approximately 43.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a bull call spread on JBIO?
- Bull call spreads on JBIO reduce the cost of a bullish JBIO stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
- How does current JBIO implied volatility affect this bull call spread?
- JBIO ATM IV is at 152.80% with IV rank near 24.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.